WO2025180468 - POLYMORPH OF USP1 INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/180468
Publication Date
04.09.2025
International Application No.
PCT/CN2025/079735
International Filing Date
28.02.2025
Title **
[English]
POLYMORPH OF USP1 INHIBITOR
[French]
POLYMORPHE DE L'INHIBITEUR D'USP1
[Chinese]
一种USP1抑制剂的多晶型
Applicants **
QILU PHARMACEUTICAL CO., LTD.
Inventors
DING, Zhaofeng
ZHANG, Ze
FU, Qiang
ZHAO, Xuexin
CHEN, Honglei
ZHANG, Jin
LIN, Dong
GAO, Yonghong
FAN, Chuanwen
Priority Data
202410233857.1
29.02.2024
CN
202410233880.0
29.02.2024
CN
202411110689.3
13.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2483 | |
| EPO | Filing, Examination, Granting | 18486 | |
| Japan | Filing, Examination, Granting | 2494 | |
| South Korea | Filing, Examination, Granting | 2934 | |
| USA | Filing, Examination, Granting | 15540 |
Total:
41,937
Contact Us
Abstract[English]
Provided in the present invention are a polymorph and salt form of a compound 2-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-9-((2-(trifluoromethyl)-6,7-dihydro-5H-benzo[c]imidazo[1,2-a]azolin-9-yl)methyl)-9H-pyrimido[4,5-b]indole-7-nitrile of formula (I). The polymorph and salt form provided by the present invention have good chemical stability and physical stability, low hygroscopicity, and are less affected by heat, humidity and illumination, thereby facilitating storage and preparation into formulations.[French]
La présente invention concerne un polymorphe et une forme de sel d'un composé 2-(4-cyclopropyl-6-méthoxypyrimidine-5-yl)-9-((2-(trifluorométhyl)-6,7-dihydro-5H-benzo[c]imidazo[1,2-a]azolin-9-yl)méthyl)-9H-pyrimido[4,5-b]indole-7-nitrile de formule (I). Le polymorphe et la forme de sel décrits par la présente invention présentent une bonne stabilité chimique et une bonne stabilité physique, une faible hygroscopicité, et sont moins affectés par la chaleur, l'humidité et l'éclairage, ce qui facilite le stockage et la préparation en formulations.[Chinese]
本发明提供了一种式(Ⅰ)化合物2-(4-环丙基-6-甲氧基嘧啶-5-基)-9-((2-(三氟甲基)-6,7-二氢-5H-苯并[c]咪唑并[1，2-a]氮杂啉-9基)甲基)-9H-嘧啶并[4,5-b]吲哚-7-腈的多晶型及盐型，本发明提供的晶型及盐型具有较好的化学稳定性、物理稳定性以及较低的吸湿性，受热、湿度和光照影响较小，便于储存及制剂。